ASP.TO Stock - Acerus Pharmaceuticals Corporation
Unlock GoAI Insights for ASP.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $-4,133,000 | $1.08M | $3.77M | $7.38M | $6.44M |
| Gross Profit | $-5,251,000 | $-929,000 | $1.57M | $-2,947,000 | $3.18M |
| Gross Margin | 127.1% | -85.6% | 41.6% | -39.9% | 49.4% |
| Operating Income | $-32,178,000 | $-21,256,000 | $-11,500,000 | $-13,901,000 | $-6,952,000 |
| Net Income | $-35,456,000 | $-24,424,000 | $-16,129,000 | $-18,786,000 | $-8,714,000 |
| Net Margin | 857.9% | -2251.1% | -428.1% | -254.7% | -135.2% |
| EPS | $-4.61 | $-16.70 | $-11.03 | $-14.59 | $-7.13 |
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Visit WebsiteEarnings History & Surprises
ASP.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 8, 2023 | — | — | — | — |
Q1 2023 | Mar 13, 2023 | — | — | — | — |
Q3 2022 | Sep 30, 2022 | — | $-1.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.54 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.37 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.48 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.81 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.14 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.10 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.79 | — | — |
Q4 2020 | Nov 3, 2020 | — | $-1.86 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.51 | — | — |
Q1 2020 | Mar 3, 2020 | — | $-2.97 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.02 | — | — |
Q4 2019 | Nov 13, 2019 | — | $-4.08 | — | — |
Q3 2019 | Aug 6, 2019 | — | $-2.00 | — | — |
Q2 2019 | May 10, 2019 | $-2.00 | $-4.00 | -100.0% | ✗ MISS |
Q4 2018 | Dec 31, 2018 | — | $-5.34 | — | — |
Q4 2018 | Nov 5, 2018 | $-2.00 | $-2.00 | 0.0% | = MET |
Q3 2018 | Aug 10, 2018 | $-6.00 | $-6.00 | 0.0% | = MET |
Latest News
Frequently Asked Questions about ASP.TO
What is ASP.TO's current stock price?
What is the analyst price target for ASP.TO?
What sector is Acerus Pharmaceuticals Corporation in?
What is ASP.TO's market cap?
Does ASP.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ASP.TO for comparison